spacer
home > ebr > summer 2019 > the future of r&d in alzheimer’s disease
PUBLICATIONS
European Biopharmaceutical Review

The Future of R&D in Alzheimer’s Disease

Earlier this year, the failures of two high-profile, antiamyloid- beta (Aβ) monoclonal antibodies (mAbs) in late-stage clinical trials have sharpened the focus on two key issues that currently dominate the quest to establish effective treatments for Alzheimer’s disease (AD): the need to develop drugs that are highly selective for the Aß conformation known to be the pathogenic cause of AD (ie, soluble neurotoxic Aβ oligomers [AβOs]) and the need to employ emerging AD biomarkers to dramatically transform clinical trial design and enable cost-effective, earlier go/nogo decisions on investigational therapeutics.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
5
     

There are no comments in regards to this article.

spacer
Dr Neil Cashman is a Physician and Scientist recognised worldwide as one of the leading researchers pioneering the emerging fields of prion biology and protein misfolding disease, in particular, Alzheimer’s disease and amyotrophic lateral sclerosis. His research has attracted more than US $50 million in funding, including grants from the National Institutes of Health. Neil is a past recipient of the Jonas Salk Prize for biomedical research and current Fellow of the Canadian Academy of Health Sciences.

Dr James W Kupiec has led both early- and late-stage development teams working on investigational therapies for a wide variety of neurologic and psychiatric disorders for the past 25 years. He began his career practising internal medicine, serving on faculty at both the University of Rochester School of Medicine, US, and the SUNY Upstate Medical University, US, before shifting to commercial posts. James most recently served as Vice President, Global Clinical Leader for Parkinson’s Disease, and Clinical Head of the Neuroscience Research Unit in Cambride for Pfizer.
spacer
Dr Neil Cashman
spacer
spacer
spacer
Dr James W Kupiec
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPI to showcase results from BioStreamline project developing novel biotherapeutics

CPI, a UK-based technology innovation centre and a founding member of the High Value Manufacturing Catapult, announced today that it will host an event in Darlington, UK on 26 June 2019 to disseminate the results of the £11.2M BioStreamline project to optimise the development of novel therapeutics. During the event, the project partners — Lonza Biologics, UCB Celltech, Sphere Fluidics, Horizon Discovery Group plc (Horizon), Alcyomics Ltd and CPI — will showcase the results and discuss the potential impact on overcoming some of the most significant shortcomings of the biologics supply chain.
More info >>

White Papers

By Your Side for a Healthier World

West Pharmaceutical Services, Inc.

Every day, injectable drugs are administered to improve the lives of millions of patients around the world. And every day, West is working by your side to design and manufacture drug packaging and delivery systems that will bring our customers’ drugs from concept to the patient more efficiently, reliably and safely. West understands our customers’ challenges and helps with solutions every step of the way, with cutting-edge production technologies, an unmatched expertise in global regulatory compliance, and an ever-growing knowledge base of pharmaceutical drug product testing, development, packaging and delivery. Whether focused on one piece of the process or an end-to-end solution, West is by your side for a healthier world.
More info >>

 
Industry Events

ELRIG Drug Discovery 2019 – Looking Back to the Future

5-6 November 2019, ACC, Liverpool

Now in its 13th year, ELRIG’s flagship conference Drug Discovery 2019 will take place at ACC in Liverpool. This year’s focus, ‘A Look Back to the Future’ is planned to include plenary introductions assessing how we got to where we are now and setting the challenges for discovering the drugs of the future. These will be followed by cutting edge talks and examples of new directions in drug discovery. Our scientific programme will feature over 40 world-class speakers with 6 main session tracks. In partnership with key academic and charitable groups, we will also run joint disease and biology-oriented tracks focusing on the basic sciences that underpin successful drug discovery.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement